PHBI (Pharmagreen Biotech) Total Liabilities: $2.29 Mil (As of Jun. 2023)


What is Pharmagreen Biotech Total Liabilities?

Pharmagreen Biotech PHBI Total Liabilities is $2.29 Mil as of Jun. 2023.

Pharmagreen Biotech's Total Liabilities for the quarter that ended in Jun. 2023 was $2.29 Mil.

Pharmagreen Biotech's quarterly Total Liabilities increased from Dec. 2022 ($2.01 Mil) to Mar. 2023 ($2.15 Mil) and increased from Mar. 2023 ($2.15 Mil) to Jun. 2023 ($2.29 Mil).

Pharmagreen Biotech's annual Total Liabilities declined from Sep. 2020 ($3.20 Mil) to Sep. 2021 ($2.07 Mil) and declined from Sep. 2021 ($2.07 Mil) to Sep. 2022 ($2.03 Mil).

Pharmagreen Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech Total Liabilities Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Total Liabilities
Get a 7-Day Free Trial 1.84 1.47 3.20 2.07 2.03

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 2.03 2.01 2.15 2.29

Pharmagreen Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharmagreen Biotech's Total Liabilities for the fiscal year that ended in Sep. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.912+(0.119+0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.03

Total Liabilities=Total Assets (A: Sep. 2022 )-Total Equity (A: Sep. 2022 )
=0.209--1.823
=2.03

Pharmagreen Biotech's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.172+(0.12+-0.0010000000000002
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.29

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=0.14--2.151
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.29 Mil mean?
Pharmagreen Biotech (PHBI) has a Total Liabilities of $2.29 Mil as of Jun. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Total Liabilities too high?
Pharmagreen Biotech's current Total Liabilities is $2.29 Mil.
How does Pharmagreen Biotech's Total Liabilities compare to DVLP and CSTF?
Pharmagreen Biotech's Total Liabilities of $2.29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current Total Liabilities is $2.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Total Liabilities of $2.29 Mil. The current Total Liabilities is $2.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Total Liabilities is $2.29 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.